Gilead Sciences Inc.

GILD-Q

NASDAQ:GILD

60.79
0.12 (0.20%)
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes drugs.
More at Wikipedia

Analysis and Opinions about GILD-Q

Signal
Opinion
Expert
BUY
BUY
April 20, 2018

He thinks the downward pressure is almost done on price. They are building an arsenal in the oncology and HIV areas. They have a good pipeline of opportunities and he likes management. He would buy it here.

Show full opinionHide full opinion

He thinks the downward pressure is almost done on price. They are building an arsenal in the oncology and HIV areas. They have a good pipeline of opportunities and he likes management. He would buy it here.

COMMENT
COMMENT
March 21, 2018

It's been painful to own. Their primary drug cured hepatitis C, the holy grail. But there's little recurring revenue here, and it disappointed investors by not reinvesting their cash. However, their new HIV franchise could take market share. A hated stock for a long time, but that sentiment is now changing. Your patience is now being rewarded.

Show full opinionHide full opinion

It's been painful to own. Their primary drug cured hepatitis C, the holy grail. But there's little recurring revenue here, and it disappointed investors by not reinvesting their cash. However, their new HIV franchise could take market share. A hated stock for a long time, but that sentiment is now changing. Your patience is now being rewarded.

BUY
BUY
March 20, 2018

He likes the company. It had some difficulties but is recovering slowly. He likes the prospects for the business. (Analysts’ price target is 89$)

Show full opinionHide full opinion

He likes the company. It had some difficulties but is recovering slowly. He likes the prospects for the business. (Analysts’ price target is 89$)

PAST TOP PICK
PAST TOP PICK
March 14, 2018

(A Top Pick June 2/17 Up 28%). He still likes this company and sees it as a value play. His model price is $100. He would love to see another pullback to $65 to buy more, but suspects it will continue to move higher.

Show full opinionHide full opinion

(A Top Pick June 2/17 Up 28%). He still likes this company and sees it as a value play. His model price is $100. He would love to see another pullback to $65 to buy more, but suspects it will continue to move higher.

PAST TOP PICK
PAST TOP PICK
March 12, 2018

(A Top Pick Feb.23, 2017, Up 23%) Their HIV business continues to grow. Their Hep C business was so good it was curing people too quickly, so their revenue declined. He bought it when the market was undervaluing both businesses. Meanwhile, GILD had lots of cash, so he expected them to do a deal. They did one for a company treating blood cancer, and that's working well. Should continue to grow rapidly and make another acquisition.

Show full opinionHide full opinion

(A Top Pick Feb.23, 2017, Up 23%) Their HIV business continues to grow. Their Hep C business was so good it was curing people too quickly, so their revenue declined. He bought it when the market was undervaluing both businesses. Meanwhile, GILD had lots of cash, so he expected them to do a deal. They did one for a company treating blood cancer, and that's working well. Should continue to grow rapidly and make another acquisition.

WATCH
WATCH
February 20, 2018

Really good valuation, but down 30% from highs three years ago. Known as the hepatitis C virus company, but the constant push-down on this stock is competition on the hepatitis C program. Done some M&A which pleased investors.

Owned it when a lot of people exited pharma during the U.S. election when candidates threatened these stocks. Better investments in other sectors like tech. That said, he doesn't own it now, but would love to own it later.

Show full opinionHide full opinion

Really good valuation, but down 30% from highs three years ago. Known as the hepatitis C virus company, but the constant push-down on this stock is competition on the hepatitis C program. Done some M&A which pleased investors.

Owned it when a lot of people exited pharma during the U.S. election when candidates threatened these stocks. Better investments in other sectors like tech. That said, he doesn't own it now, but would love to own it later.

BUY
BUY
February 2, 2018

Issues about competition with its drugs. Earns 26% ROIC, EBITDA has come down. In a good area, including oncology and HIV. A good pipeline, cash flow and valuations. Likes it a lot.

Show full opinionHide full opinion

Issues about competition with its drugs. Earns 26% ROIC, EBITDA has come down. In a good area, including oncology and HIV. A good pipeline, cash flow and valuations. Likes it a lot.

PAST TOP PICK
PAST TOP PICK
February 1, 2018

(A Top Pick January 16/17. Up 14.3%) A pharmaceutical company. It collapsed at that time and that is why they bought it trading at 8 times earnings. It has a good dividend yield. It has two drugs. One of the drugs is curing everybody and revenue coming from there was falling and the market people overemphasize that. They have a lot of cash on hand. They think it could buy more things like a recent very good acquisition of a company with a new technique to fight cancer.

Show full opinionHide full opinion

(A Top Pick January 16/17. Up 14.3%) A pharmaceutical company. It collapsed at that time and that is why they bought it trading at 8 times earnings. It has a good dividend yield. It has two drugs. One of the drugs is curing everybody and revenue coming from there was falling and the market people overemphasize that. They have a lot of cash on hand. They think it could buy more things like a recent very good acquisition of a company with a new technique to fight cancer.

DON'T BUY
DON'T BUY
January 11, 2018

They had a great pop. He stepped out of Biotech and healthcare as a sector went to a neutral. He is more cautious on this as the entry gets higher.

Show full opinionHide full opinion

They had a great pop. He stepped out of Biotech and healthcare as a sector went to a neutral. He is more cautious on this as the entry gets higher.

PAST TOP PICK
PAST TOP PICK
December 29, 2017

(A Top Pick Dec 30/16. Up 3%.) A biotech company. Had 2 big products, a hep C drug and an HIV drug. The HIV drugs are doing quite well. The hep C drug is so good it cured people faster than expected. The stock ran up on the hep C drug, and is now declining. They have a lot of cash and acquired a pharmaceuticals company, which is a good acquisition for them. Good dividend yield and they should benefit from tax reform. He still likes this.

Show full opinionHide full opinion

(A Top Pick Dec 30/16. Up 3%.) A biotech company. Had 2 big products, a hep C drug and an HIV drug. The HIV drugs are doing quite well. The hep C drug is so good it cured people faster than expected. The stock ran up on the hep C drug, and is now declining. They have a lot of cash and acquired a pharmaceuticals company, which is a good acquisition for them. Good dividend yield and they should benefit from tax reform. He still likes this.

DON'T BUY
DON'T BUY
December 19, 2017

Has always shied away from this. They had a very successful ramp with their HEP C drug portfolio, a peak, followed by a fairly rapid decline. The decline came on a couple of issues. It was a total cure so there wasn't a recurring customer. Also, a number of other pharmacies came out with products that competed effectively, so there was price competition. The HEP C portfolio is falling about 40% year-over-year.

Show full opinionHide full opinion

Has always shied away from this. They had a very successful ramp with their HEP C drug portfolio, a peak, followed by a fairly rapid decline. The decline came on a couple of issues. It was a total cure so there wasn't a recurring customer. Also, a number of other pharmacies came out with products that competed effectively, so there was price competition. The HEP C portfolio is falling about 40% year-over-year.

WAIT
WAIT
December 12, 2017

Has a very strong balance sheet, and is looking for future growth. They’re not able to satisfy that organically, so are going out to make acquisitions. They announced one a few months ago, and expects they are going to continue to look. However, they are not cheap, so Gilead may have to pay a very full price. The company is well-managed and owns fine assets, but she would wait.

Show full opinionHide full opinion

Has a very strong balance sheet, and is looking for future growth. They’re not able to satisfy that organically, so are going out to make acquisitions. They announced one a few months ago, and expects they are going to continue to look. However, they are not cheap, so Gilead may have to pay a very full price. The company is well-managed and owns fine assets, but she would wait.

WATCH
WATCH
November 30, 2017

He bought it at this level 3 or 4 year ago. The growth has stopped. The HEP C drugs caused it to run as well but they cured people so it was not going to lend itself to a lot of recurring revenue. The worst is behind them. They have other drugs in HIV and Oncology that could get the growth back up.

Show full opinionHide full opinion

He bought it at this level 3 or 4 year ago. The growth has stopped. The HEP C drugs caused it to run as well but they cured people so it was not going to lend itself to a lot of recurring revenue. The worst is behind them. They have other drugs in HIV and Oncology that could get the growth back up.

WATCH
WATCH
November 28, 2017

Technically, this has been having a difficult time in the last little while. It has a period of seasonal strength from about mid-December to around April of each year. We are not in the period of seasonal strength yet. It is forming a base pattern. Technically, if it gets above $78 level, that would be a confirmation of the bottoming pattern and that the security is going into its period of seasonal strength.

Show full opinionHide full opinion

Technically, this has been having a difficult time in the last little while. It has a period of seasonal strength from about mid-December to around April of each year. We are not in the period of seasonal strength yet. It is forming a base pattern. Technically, if it gets above $78 level, that would be a confirmation of the bottoming pattern and that the security is going into its period of seasonal strength.

DON'T BUY
DON'T BUY
November 23, 2017

This has recently gone higher, to about $80, so there will be people wanting to sell. Avoid. You may have to wait a couple of years before the oversupply can be digested. Dividend yield of 2.86%.

Show full opinionHide full opinion

This has recently gone higher, to about $80, so there will be people wanting to sell. Avoid. You may have to wait a couple of years before the oversupply can be digested. Dividend yield of 2.86%.

Showing 31 to 45 of 241 entries